R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Director – Biostatistics - Early Phase

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timeRedwood City, CA, USAIn-person

About the Job

Requirements

  • A Ph.D. or M.S. in Statistics or Biostatistics and at least 8 years of biotech/pharma clinical-trial statistician experience for Ph.D. candidates, or at least 12 years for M.S. candidates; level depends on experience relevance.
  • Hands-on experience designing and analyzing oncology trials.
  • Ability to work independently and within a team.
  • Ability to apply statistical knowledge to practical problems and acquire knowledge of advanced statistical methods, including Bayesian methods and predictive modeling.
  • Proficiency in SAS and/or R.

Responsibilities

  • Serve as lead statistician for oncology studies and coordinate activities with other functional groups to ensure timely deliverables.
  • Represent biostatistics on study and project teams.
  • Provide statistical expertise for clinical study design, analysis, and reporting.
  • Collaborate with functions on study design and planning, protocol development, statistical methodology, and analysis.
  • Develop statistical analysis plans and analysis specifications.
  • Collaborate with statistical programming to ensure analyses follow the statistical plan and specifications.
  • Collaborate with data management and clinical operations on robust database development and quality data collection.
  • Provide statistical input to regulatory interactions and responses to health authority submissions.
  • Collaborate on publications, assist with data interpretation, and ensure consistency and accuracy in data presentation.
  • Contribute to functional-level standards, SOPs, and templates.
  • Keep abreast of developments in statistics, drug development, and regulatory guidance, and share knowledge with functional and cross-functional team members.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs